Format

Send to

Choose Destination
Curr Neuropharmacol. 2017;15(6):926-935. doi: 10.2174/1570159X15666170116143743.

The Amyloid Cascade Hypothesis in Alzheimer's Disease: It's Time to Change Our Mind.

Author information

1
Department of Experimental Medicine, Section of General Pathology, University of Genova, Genova, Italy.
2
Department of Pharmacy, Section of Pharmacology and Toxicology, University of Genova, Genova, Italy.

Abstract

Since its discovery in 1984, the beta amyloid peptide has treaded the boards of neurosciences as the star molecule in Alzheimer's disease pathogenesis. In the last decade, however, this vision has been challenged by evidence-based medicine showing the almost complete failure of clinical trials that experimented anti-amyloid therapies with great hopes. Moreover, data have accumulated which clearly indicate that this small peptide plays a key role in the physiological processes of memory formation. In the present review, we will discuss the different aspects of the amyloid cascade hypothesis, highlighting its pros and cons, and we will analyse the results of the therapeutic approaches attempted to date that should change the direction of Alzheimer's disease research in the future.

KEYWORDS:

Alzheimer's disease; LTP; anti-amyloid therapy; beta amyloid; clinical trials; memory

PMID:
28093977
PMCID:
PMC5652035
DOI:
10.2174/1570159X15666170116143743
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd. Icon for PubMed Central
Loading ...
Support Center